Evidence-based Evaluation of Fracture Risk in Clinical Therapy with Proton Pump Inhibitors

Hui-bo LI,Rong-sheng ZHAO
DOI: https://doi.org/10.3969/j.issn.1672-3384.2014.03.001
2014-01-01
Abstract:Objective: Several studies demonstrate the possible increased risk of fractures with the use of long-term and/or high dose proton pump inhibitors, including hip, wrist, and spine fractures. In order to more rational medical therapy in several acid-related upper gastrointestinal disorders with PPI and better control of the fracture risk, therefore, we performed anevidence-based systematic review with existing studies to explain the possible mechanism of potential risk and to evaluate the association between the use of PPI and risks for fracture. Methods: We searched PubMed, the Cochrane Central, EMbase, CNKI, CBM, VIP and WanFang Data from inception through October 2013 using common key words with the setting outcome fracture.We use Austin Bradford-Hil criteria to the evaluate of causal association in PPI use and risk of fracture. We evaluate the quality of the evidence across studies according to the approach of the GRADE working group. Results and Conclusion: The search strategy identified 619 English articles and 142 Chinese articles, including 6 cohort studies, 9 case-control studies and 6 system reviews and meta-analysis. We found a modest association between PPI use and increased risk of hip, wrist and spine fractures through the observational studies.Long-term duration and high dose use of PPI increase the risk of hip fracture.The ORs from the meta-analysis are al less than 2 with the significant statistical and clinical heterogeneity among studies.The studies according to GRADE working group evaluation of the quality are very low evidence.More high-quality evidence is needed in the future to assess the risk of adverse reactions.For patients with long-term use of PPI should choose the minimum maintenance dose, considering intermittent medication or switch to H2RA.
What problem does this paper attempt to address?